Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF

Journal of Medicinal Chemistry

Volumn 59, Issue 4, 2016, Pages 1642-1647

  Bennett, James ^a,b   Fedorov, Oleg ^a,b   Tallant, Cynthia ^a,b   Monteiro, Octovia ^a,b   Meier, Julia ^b   Gamble, Vicky ^b   Savitsky, Pavel ^a,b   Nunez Alonso, Graciela A ^a,b   Haendler, Bernard ^d   Rogers, Catherine ^a,b   Brennan, Paul E ^a,b   Müller, Susanne ^a,b   Knapp, Stefan ^a,b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GOETHE UNIVERSITY   (Germany)

^d BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN INHIBITOR; CYTOTOXIC AGENT; BENZIMIDAZOLE DERIVATIVE; BENZIMIDAZOLONE; BRPF1 PROTEIN, HUMAN; CARRIER PROTEIN; LYSINE; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRIM24 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG TARGETING; ENTROPY; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; ISOTHERMAL TITRATION CALORIMETRY; MCF 7 CELL LINE; MYELOMA; NUCLEAR LOCALIZATION SIGNAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR DOCKING; MOLECULAR MODEL; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BENZIMIDAZOLES; CARRIER PROTEINS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; HUMANS; LYSINE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY;

EID: 84959421867     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00458     Document Type: Article

References (34)

1. Muller, S.; Filippakopoulos, P.; Knapp, S. Bromodomains as therapeutic targets Expert Rev. Mol. Med. 2011, 13, e29
2. Filippakopoulos, P.; Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation Nature Rev. Drug Discovery 2014, 13, 337-356
3. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067-1073
4. Dawson, M. A.; Prinjha, R. K.; Dittmann, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W. I.; Robson, S. C.; Chung, C. W.; Hopf, C.; Savitski, M. M.; Huthmacher, C.; Gudgin, E.; Lugo, D.; Beinke, S.; Chapman, T. D.; Roberts, E. J.; Soden, P. E.; Auger, K. R.; Mirguet, O.; Doehner, K.; Delwel, R.; Burnett, A. K.; Jeffrey, P.; Drewes, G.; Lee, K.; Huntly, B. J.; Kouzarides, T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 2011, 478, 529-533
5. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 2011, 146, 904-917
6. Picaud, S.; Da Costa, D.; Thanasopoulou, A.; Filippakopoulos, P.; Fish, P. V.; Philpott, M.; Fedorov, O.; Brennan, P.; Bunnage, M. E.; Owen, D. R.; Bradner, J. E.; Taniere, P.; O'Sullivan, B.; Muller, S.; Schwaller, J.; Stankovic, T.; Knapp, S. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains Cancer Res. 2013, 73, 3336-3346
7. Cheng, Z.; Gong, Y.; Ma, Y.; Lu, K.; Lu, X.; Pierce, L. A.; Thompson, R. C.; Muller, S.; Knapp, S.; Wang, J. Inhibition of BET bromodomain targets genetically diverse glioblastoma Clin. Cancer Res. 2013, 19, 1748-1759
8. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C. W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of inflammation by a synthetic histone mimic Nature 2010, 468, 1119-1123
9. Hay, D. A.; Fedorov, O.; Martin, S.; Singleton, D. C.; Tallant, C.; Wells, C.; Picaud, S.; Philpott, M.; Monteiro, O. P.; Rogers, C. M.; Conway, S. J.; Rooney, T. P.; Tumber, A.; Yapp, C.; Filippakopoulos, P.; Bunnage, M. E.; Muller, S.; Knapp, S.; Schofield, C. J.; Brennan, P. E. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains J. Am. Chem. Soc. 2014, 136, 9308-9319
10. Fedorov, O.; Lingard, H.; Wells, C.; Monteiro, O. P.; Picaud, S.; Keates, T.; Yapp, C.; Philpott, M.; Martin, S. J.; Felletar, I.; Marsden, B. D.; Filippakopoulos, P.; Muller, S.; Knapp, S.; Brennan, P. E. [1,2,4]Triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains J. Med. Chem. 2014, 57, 462-476
11. Demont, E. H.; Bamborough, P.; Chung, C. W.; Craggs, P. D.; Fallon, D.; Gordon, L. J.; Grandi, P.; Hobbs, C. I.; Hussain, J.; Jones, E. J.; Le Gall, A.; Michon, A. M.; Mitchell, D. J.; Prinjha, R. K.; Roberts, A. D.; Sheppard, R. J.; Watson, R. J. 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain ACS Med. Chem. Lett. 2014, 5, 1190-1195
12. Rooney, T. P.; Filippakopoulos, P.; Fedorov, O.; Picaud, S.; Cortopassi, W. A.; Hay, D. A.; Martin, S.; Tumber, A.; Rogers, C. M.; Philpott, M.; Wang, M.; Thompson, A. L.; Heightman, T. D.; Pryde, D. C.; Cook, A.; Paton, R. S.; Muller, S.; Knapp, S.; Brennan, P. E.; Conway, S. J. A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-pi interaction Angew. Chem., Int. Ed. Engl. 2014, 53, 6126-6130
13. Vidler, L. R.; Brown, N.; Knapp, S.; Hoelder, S. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites J. Med. Chem. 2012, 55, 7346-7359
14. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J. P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T.; Gingras, A. C.; Arrowsmith, C. H.; Knapp, S. Histone recognition and large-scale structural analysis of the human bromodomain family Cell 2012, 149, 214-231
15. Filippakopoulos, P.; Knapp, S. The bromodomain interaction module FEBS Lett. 2012, 586, 2692-2704
16. Vidler, L. R.; Filippakopoulos, P.; Fedorov, O.; Picaud, S.; Martin, S.; Tomsett, M.; Woodward, H.; Brown, N.; Knapp, S.; Hoelder, S. Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening J. Med. Chem. 2013, 56, 8073-8088
17. Ciceri, P.; Muller, S.; O'Mahony, A.; Fedorov, O.; Filippakopoulos, P.; Hunt, J. P.; Lasater, E. A.; Pallares, G.; Picaud, S.; Wells, C.; Martin, S.; Wodicka, L. M.; Shah, N. P.; Treiber, D. K.; Knapp, S. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology Nature Chem. Biol. 2014, 10, 305-312
18. Ember, S. W.; Zhu, J. Y.; Olesen, S. H.; Martin, M. P.; Becker, A.; Berndt, N.; Georg, G. I.; Schonbrunn, E. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors ACS Chem. Biol. 2014, 9, 1160-1171
19. Tsai, W. W.; Wang, Z.; Yiu, T. T.; Akdemir, K. C.; Xia, W.; Winter, S.; Tsai, C. Y.; Shi, X.; Schwarzer, D.; Plunkett, W.; Aronow, B.; Gozani, O.; Fischle, W.; Hung, M. C.; Patel, D. J.; Barton, M. C. TRIM24 links a non-canonical histone signature to breast cancer Nature 2010, 468, 927-932
20. Zhang, L. H.; Yin, A. A.; Cheng, J. X.; Huang, H. Y.; Li, X. M.; Zhang, Y. Q.; Han, N.; Zhang, X. TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway Oncogene 2015, 34, 600-610
21. Liu, X.; Huang, Y.; Yang, D.; Li, X.; Liang, J.; Lin, L.; Zhang, M.; Zhong, K.; Liang, B.; Li, J. Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma PLoS One 2014, 9, e85462
22. Miao, Z. F.; Wang, Z. N.; Zhao, T. T.; Xu, Y. Y.; Wu, J. H.; Liu, X. Y.; Xu, H.; You, Y.; Xu, H. M. TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance Virchows Arch. 2015, 466, 525-532
23. Li, H.; Sun, L.; Tang, Z.; Fu, L.; Xu, Y.; Li, Z.; Luo, W.; Qiu, X.; Wang, E. Overexpression of TRIM24 correlates with tumor progression in non-small cell lung cancer PLoS One 2012, 7, e37657
24. Cui, Z.; Cao, W.; Li, J.; Song, X.; Mao, L.; Chen, W. TRIM24 overexpression is common in locally advanced head and neck squamous cell carcinoma and correlates with aggressive malignant phenotypes PLoS One 2013, 8, e63887
25. Theurillat, J. P.; Udeshi, N. D.; Errington, W. J.; Svinkina, T.; Baca, S. C.; Pop, M.; Wild, P. J.; Blattner, M.; Groner, A. C.; Rubin, M. A.; Moch, H.; Prive, G. G.; Carr, S. A.; Garraway, L. A. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer Science 2014, 346, 85-89
26. Allton, K.; Jain, A. K.; Herz, H. M.; Tsai, W. W.; Jung, S. Y.; Qin, J.; Bergmann, A.; Johnson, R. L.; Barton, M. C. Trim24 targets endogenous p53 for degradation Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 11612-11616
27. Le Douarin, B.; Nielsen, A. L.; Garnier, J. M.; Ichinose, H.; Jeanmougin, F.; Losson, R.; Chambon, P. A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors EMBO J. 1996, 15, 6701-6715
28. Wang, J.; Zhu, J.; Dong, M.; Yu, H.; Dai, X.; Li, K. Knockdown of tripartite motif containing 24 by lentivirus suppresses cell growth and induces apoptosis in human colorectal cancer cells Oncol. Res. 2014, 22, 39-45
29. Pathiraja, T. N.; Thakkar, K. N.; Jiang, S.; Stratton, S.; Liu, Z.; Gagea, M.; Shi, X.; Shah, P. K.; Phan, L.; Lee, M. H.; Andersen, J.; Stampfer, M.; Barton, M. C. TRIM24 links glucose metabolism with transformation of human mammary epithelial cells Oncogene 2014, 10.1038/onc.2014.220
30. Khetchoumian, K.; Teletin, M.; Tisserand, J.; Mark, M.; Herquel, B.; Ignat, M.; Zucman-Rossi, J.; Cammas, F.; Lerouge, T.; Thibault, C.; Metzger, D.; Chambon, P.; Losson, R. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha Nature Genet. 2007, 39, 1500-1506
31. Fedorov, O.; Niesen, F. H.; Knapp, S. Kinase inhibitor selectivity profiling using differential scanning fluorimetry Methods Mol. Biol. 2012, 795, 109-118
32. Drouin, L.; McGrath, S.; Vidler, L. R.; Chaikuad, A.; Monteiro, O.; Tallant, C.; Philpott, M.; Rogers, C.; Fedorov, O.; Liu, M.; Akhtar, W.; Hayes, A.; Raynaud, F.; Muller, S.; Knapp, S.; Hoelder, S. Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B J. Med. Chem. 2015, 58, 2553-2559
33. Philpott, M.; Rogers, C. M.; Yapp, C.; Wells, C.; Lambert, J. P.; Strain-Damerell, C.; Burgess-Brown, N. A.; Gingras, A. C.; Knapp, S.; Muller, S. Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching Epigenetics Chromatin 2014, 7, 14
34. Poplawski, A.; Hu, K.; Lee, W.; Natesan, S.; Peng, D.; Carlson, S.; Shi, X.; Balaz, S.; Markley, J. L.; Glass, K. C. Molecular insights into the recognition of N-terminal histone modifications by the BRPF1 bromodomain J. Mol. Biol. 2014, 426, 1661-1676